The Novasep-PharmaZell Group has announced a €7.3M investment for its Mourenx site (southwestern France), as part of a larger project supported by the "France Relance" Plan, to create a multipurpose pilot workshop within one of its production units. This new industrial tool will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.
This investment includes an upgrade of two existing 2000-liter reactors to optimize their versatility and functionality, together with the addition of a new 1500-liter reactor & Hastelloy filter-dryer. The new multi-purpose workshop will be equipped to produce batches ranging from 30 to 100 kg for clinical trials, process validation and commercial production of APIs for targeted therapies, with a focus on HPAPIs.